This paper presents the study protocol for the ADAP-TIV trial, a research project designed to tackle one of the most significant challenges in global health: ensuring medication adherence for patients facing the "syndemic" of multi-drug resistant tuberculosis (MDR-TB) and HIV.
TL;DR
The ADAP-TIV trial uses a Bayesian adaptive randomized design to evaluate four different strategies—ranging from digital mHealth tools to intensive psychosocial support—for improving treatment outcomes in South African patients with MDR-TB and HIV. By titrating the intensity of support based on individual patient needs, the study aims to identify the most effective way to deploy modern, all-oral drug regimens in high-burden settings.
What Problem Does This Paper Address?
While medical science has recently produced highly effective, all-oral treatment regimens for MDR-TB (like bedaquiline) and advanced antiretroviral therapy (ART) for HIV, these drugs only work if patients take them consistently. In South Africa, where over half of TB patients are co-infected with HIV, the treatment burden is immense.
Traditionally, TB programs relied on Directly Observed Therapy (DOT), where a healthcare worker physically watches a patient swallow their pills. This "one-size-fits-all" approach is often rigid, paternalistic, and difficult for patients to maintain over long periods. There is a critical gap in knowing how to transition to Differentiated Service Delivery (DSD)—a patient-centered model that tailors the level of support to the individual’s specific clinical and social needs.
Methods
The ADAP-TIV trial is a prospective, four-arm, adaptive randomized controlled trial (RCT).
The Four Arms:
- Enhanced Standard of Care: Usual clinic care plus extra treatment literacy training for staff.
- Psychosocial Support: Monthly counseling, adherence support groups, and home visits.
- mHealth: Use of the Wisepill RT3000, a cellular-enabled electronic pillbox that records every opening. Patients receive weekly SMS reminders and "rescue" calls if doses are missed.
- Combined Support: Both mHealth and psychosocial interventions.
Key Innovations:
- Bayesian Adaptive Randomization: Unlike traditional RCTs with fixed 1:1 randomization, this trial uses a "run-in" period for the first 40 participants. After that, a Bayesian algorithm modifies the randomization weights to favor the arms that are showing better preliminary results. This is more ethical (more patients get the "better" treatment) and statistically efficient.
- Titrated Support: Within each arm, the intensity of the intervention is not static. If a patient shows signs of struggling (e.g., low adherence scores or missed pillbox openings), the frequency of counseling or phone check-ins increases.
Datasets
As a study protocol, the paper describes the planned data collection rather than a completed dataset.
- Target Population: 400 adult patients with confirmed MDR-TB and HIV.
- Setting: Durban, South Africa (specifically the King Dinuzulu Hospital and KwaMashu community clinic).
- Primary Outcome: A composite clinical endpoint at 12 months, including survival, negative TB culture, retention in care, and undetectable HIV viral load.
Key Insights and Ideas
- The DSD Framework for TB: The study represents a major shift from "watching the patient" to "supporting the patient." It applies the DSD framework—already successful in HIV care—to the more complex MDR-TB/HIV co-infection cascade.
- Electronic Dose Monitoring (EDM) as a Proxy: By using the Wisepill device, researchers can treat "pillbox opening" as a real-time surrogate for adherence. This allows for immediate intervention before a patient's viral load rises or their TB culture reverts to positive.
- Addressing the "Syndemic": The trial recognizes that TB and HIV cannot be treated in silos. The primary outcome is a "composite success" measure, acknowledging that a patient is only truly healthy if both infections are managed simultaneously.
Key Results
As this is a protocol paper, quantitative results are not yet available. However, the authors provide a detailed Power Analysis (Table 3).
- The study is powered to detect a superior arm with a probability (power) ranging from 74% to 98%, depending on the actual success rates of the interventions (estimated between 70% and 90%).
- The trial began recruitment in March 2023, with an estimated completion date in March 2027.
Limitations and Future Work
- Cost of Technology: The Wisepill devices cost approximately $100 each. While the authors argue that preventing treatment failure is more cost-effective in the long run, the initial price point may be a barrier for scale-up in low-income countries.
- Generalizability: The trial is centered in KwaZulu-Natal, the global epicenter of the TB/HIV epidemic. While the results will be highly relevant to Southern Africa, they may not perfectly translate to regions with different cultural or structural barriers to care (e.g., Southeast Asia).
- Refractory Barriers: The authors acknowledge that some patients face "deep-seated" behavioral or structural challenges (like extreme poverty or severe stigma) that even intensive psychosocial or digital support may not fully overcome. Future work will likely involve a cost-effectiveness analysis to see which "titrated" model offers the best value for public health systems.
Summary updated